JP2013525310A - Ｃｏｐｄ増悪を治療するための組成物および方法 - Google Patents

Ｃｏｐｄ増悪を治療するための組成物および方法 Download PDF

Info

Publication number
JP2013525310A
JP2013525310A JP2013505212A JP2013505212A JP2013525310A JP 2013525310 A JP2013525310 A JP 2013525310A JP 2013505212 A JP2013505212 A JP 2013505212A JP 2013505212 A JP2013505212 A JP 2013505212A JP 2013525310 A JP2013525310 A JP 2013525310A
Authority
JP
Japan
Prior art keywords
antibody
copd
patient
certain embodiments
exacerbation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525310A5 (enExample
Inventor
フィンチ，ドナ
コイル，アンソニー
スタンプフリ，マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2013525310A publication Critical patent/JP2013525310A/ja
Publication of JP2013525310A5 publication Critical patent/JP2013525310A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013505212A 2010-04-16 2011-04-18 Ｃｏｐｄ増悪を治療するための組成物および方法 Pending JP2013525310A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US61/325,241 2010-04-16
US41610210P 2010-11-22 2010-11-22
US61/416,102 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (2)

Publication Number Publication Date
JP2013525310A true JP2013525310A (ja) 2013-06-20
JP2013525310A5 JP2013525310A5 (enExample) 2014-05-08

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013505212A Pending JP2013525310A (ja) 2010-04-16 2011-04-18 Ｃｏｐｄ増悪を治療するための組成物および方法

Country Status (11)

Country Link
US (1) US20130149312A1 (enExample)
EP (1) EP2558112A4 (enExample)
JP (1) JP2013525310A (enExample)
KR (1) KR20130086141A (enExample)
CN (1) CN102985100A (enExample)
AU (1) AU2011239402A1 (enExample)
BR (1) BR112012026545A2 (enExample)
CA (1) CA2796083A1 (enExample)
MX (1) MX2012012063A (enExample)
RU (1) RU2012148721A (enExample)
WO (1) WO2011130745A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182121A1 (ja) * 2014-05-29 2015-12-03 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
WO2016168696A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Methods to improve induction of iga antibodies by vaccines
WO2016197087A1 (en) 2015-06-05 2016-12-08 The University Of Rochester Shape-memory polymers and methods of making and use thereof
KR102208549B1 (ko) * 2019-05-16 2021-01-27 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
EP4069847A4 (en) * 2019-12-02 2023-11-15 Onspira Therapeutics, Inc. Treatment of lower airways disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517179A (ja) * 2002-09-06 2006-07-20 アムジェン インコーポレイテッド 治療用ヒト抗ｉ−ｉｌ−１ｒ１モノクローナル抗体
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
KR20080077238A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517179A (ja) * 2002-09-06 2006-07-20 アムジェン インコーポレイテッド 治療用ヒト抗ｉ−ｉｌ−１ｒ１モノクローナル抗体
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182121A1 (ja) * 2014-05-29 2015-12-03 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
JPWO2015182121A1 (ja) * 2014-05-29 2017-04-27 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療

Also Published As

Publication number Publication date
RU2012148721A (ru) 2014-05-27
WO2011130745A1 (en) 2011-10-20
BR112012026545A2 (pt) 2019-09-24
CA2796083A1 (en) 2011-10-20
MX2012012063A (es) 2013-03-21
EP2558112A4 (en) 2014-06-18
KR20130086141A (ko) 2013-07-31
EP2558112A1 (en) 2013-02-20
CN102985100A (zh) 2013-03-20
AU2011239402A1 (en) 2012-10-25
US20130149312A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
ES2701093T3 (es) Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
EP3613432A1 (en) Methods for treating nasal polyposis by administering an il-4r antagonist
KR20170081262A (ko) Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
ES2981704T3 (es) Métodos de tratamiento de enfermedades en las que la actividad de IL-13 es perjudicial mediante la utilización de anticuerpos anti-IL-13
JP6458086B2 (ja) 変形性関節症の治療
JP2013525310A (ja) Ｃｏｐｄ増悪を治療するための組成物および方法
KR20220143699A (ko) 인간 항-tslp 항체 제형 및 이의 이용 방법
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
JP2022509251A (ja) 急性増悪をポリクローナル免疫グロブリンで予防または治療するための方法および組成物
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025147632A1 (en) Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
US20140248289A1 (en) Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition
TR201819492T4 (tr) Bir ıl-4r antagonisti uygulayarak astımı tedavi etmek veya önlemek için yöntemler.

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150728